Published April 2021 | Version v1
Journal article Metadata-only

Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial

Creators

  • 1. Schulich School of Medicine & Dentistry, Western University, London (Canada)
  • 2. London Health Sciences Centre, London (Canada)
  • 3. Ivey Business School, Western University, London (Canada)
  • 4. Amsterdam University Medical Center, Vrije Universiteit Medical Center, Amsterdam (Netherlands)
  • 5. British Columbia Cancer, Centre for the North, Prince George (Canada)

Description

The phase 2 randomized study SABR-COMET demonstrated that in patients with controlled primary tumors and 1 to 5 oligometastatic lesions, SABR was associated with improved progression-free survival (PFS) compared with standard of care (SoC), but with higher costs and treatment-related toxicities. The aim of this study was to assess the cost-effectiveness of SABR versus SoC in this setting.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2020.12.001

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2020.12.001;
PII
S0360301620346459;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
109
Journal Issue
5
Journal Page Range
p. 1176-1184
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
53124527
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ECONOMIC ANALYSIS; NEOPLASMS; PATIENTS; RADIOTHERAPY; TOXICITY
Descriptors DEC
DISEASES; ECONOMICS; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2020 Elsevier Inc. All rights reserved.